To assess the impact of PIKfyve inhibition on non-KRAS-driven PDAC, we employed a BxPC-3 (BRAFV487-P492>A) CDX and showed that ESK981 still suppressed tumor growth and reduced tumor weight at endpoint (Extended Data Fig. 2A–C). Here, KRAS is linked to neoplasm.